{"id":26202,"date":"2026-07-09T12:45:47","date_gmt":"2026-07-09T10:45:47","guid":{"rendered":"https:\/\/adragos-pharma.com\/?p=26202"},"modified":"2026-07-10T14:49:05","modified_gmt":"2026-07-10T12:49:05","slug":"webinar-de-risking-sterile-fill-finish-from-clinical-to-commercial-adragos-pharma","status":"publish","type":"post","link":"https:\/\/adragos-pharma.com\/webinar-de-risking-sterile-fill-finish-from-clinical-to-commercial-adragos-pharma\/","title":{"rendered":"Webinar: De-Risking Sterile Fill-Finish from Clinical to Commercial | Adragos Pharma"},"content":{"rendered":"\n<div style=\"background-color:#ffffff;padding:72px 32px 64px;text-align:center;border-bottom:4px solid #f0f1f8;margin-bottom:32px;\">\n  <p style=\"color:#0EC9BB;font-size:11px;font-weight:700;text-transform:uppercase;letter-spacing:3px;margin:0 0 20px;padding:0;\">\n  <\/p><h1 style=\"color:#1C1C75;font-size:2.5rem;font-weight:800;line-height:1.22;margin:0 auto 20px;max-width:820px;\">De-Risking Sterile Fill-Finish from Clinical to Commercial<\/h1>\n  <p style=\"color:#8696FE;font-size:1.05rem;line-height:1.65;max-width:680px;margin:0 auto 16px;\">How expanded CDMO capabilities, lyophilisation expertise and a flexible facility network help accelerate sterile product success.<\/p>\n  <p style=\"color:#5a5a7a;font-size:0.96rem;line-height:1.78;max-width:700px;margin:0 auto 36px;\">Sterile product development and manufacturing can be complex. Scale-up, lyophilisation, technology transfer, quality expectations and supply continuity all need the right technical and operational support. Join Adragos Pharma for a practical webinar designed for CMC, outsourcing, MSAT, technical operations and external manufacturing teams looking to reduce risk across the sterile product lifecycle.<\/p><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-text-color\" style=\"color:#1C1C75\">Is this your programme?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This webinar is designed for teams working on sterile products where timelines, quality and supply reliability matter. It is especially relevant for:<\/p>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<ul class=\"wp-block-list\">\n<li>CMC and pharmaceutical development teams<\/li>\n\n\n\n<li>Outsourcing and external manufacturing leaders<\/li>\n\n\n\n<li>MSAT and technical operations teams<\/li>\n\n\n\n<li>Sterile manufacturing and fill-finish leads<\/li>\n\n\n\n<li>Technology transfer and industrialisation teams<\/li>\n\n\n\n<li>Procurement and supply chain decision-makers<\/li>\n\n\n\n<li>Project and programme managers supporting clinical-to-commercial progression<\/li>\n<\/ul>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-buttons has-custom-font-size has-medium-font-size is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-fe48e5de wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-secondary-background-color has-background wp-element-button\" href=\"https:\/\/share-eu1.hsforms.com\/1FVbF5kKkQ4ac7mORaiFYmwfxkpu\" target=\"_blank\" rel=\"noopener\"><strong>Watch the Webinar<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<div style=\"background-color:#f5f6fc;padding:64px 32px;\">\n  <div style=\"max-width:1100px;margin:0 auto;\">\n    <p style=\"color:#0EC9BB;font-size:11px;font-weight:700;text-transform:uppercase;letter-spacing:3px;margin:0 0 16px;padding:0;\">The Challenge<\/p>\n    <h2 style=\"color:#1C1C75;font-size:2rem;font-weight:800;line-height:1.25;margin:0 0 16px;max-width:700px;\">Sterile manufacturing is where complexity becomes operational<\/h2>\n    <p style=\"color:#5a5a7a;font-size:1rem;line-height:1.75;max-width:740px;margin:0 0 40px;\">Bringing sterile products to market requires more than capacity. Each stage introduces potential risk: process transfer, scale-up, lyophilisation, aseptic control, inspection, packaging and commercial supply planning.<\/p>\n    <div style=\"display:flex;flex-wrap:wrap;gap:20px;margin-bottom:32px;\">\n      <div style=\"flex:1;min-width:280px;background-color:#ffffff;border:1px solid #e2e4f0;border-top:3px solid #0EC9BB;border-radius:12px;padding:24px;box-shadow:0 2px 10px rgba(28,28,117,0.06);\">\n        <div style=\"font-size:1.4rem;margin-bottom:12px;\">\ud83d\udd01<\/div>\n        <h3 style=\"color:#1C1C75;font-size:1rem;font-weight:700;margin:0 0 10px;\">Process Transfer Risk<\/h3>\n        <p style=\"color:#5a5a7a;font-size:0.87rem;line-height:1.7;margin:0;\">Delays are not always caused by the science. Unclear transfer models and insufficient CDMO flexibility create execution challenges that slow programmes down.<\/p>\n      <\/div>\n      <div style=\"flex:1;min-width:280px;background-color:#ffffff;border:1px solid #e2e4f0;border-top:3px solid #0EC9BB;border-radius:12px;padding:24px;box-shadow:0 2px 10px rgba(28,28,117,0.06);\">\n        <div style=\"font-size:1.4rem;margin-bottom:12px;\">\u2744\ufe0f<\/div>\n        <h3 style=\"color:#1C1C75;font-size:1rem;font-weight:700;margin:0 0 10px;\">Lyophilisation Complexity<\/h3>\n        <p style=\"color:#5a5a7a;font-size:0.87rem;line-height:1.7;margin:0;\">Scale-up from clinical to commercial demands deep technical expertise, robust cycle development and rigorous qualification \u2014 up to ~70,000 vials per batch.<\/p>\n      <\/div>\n      <div style=\"flex:1;min-width:280px;background-color:#ffffff;border:1px solid #e2e4f0;border-top:3px solid #0EC9BB;border-radius:12px;padding:24px;box-shadow:0 2px 10px rgba(28,28,117,0.06);\">\n        <div style=\"font-size:1.4rem;margin-bottom:12px;\">\ud83c\udfed<\/div>\n        <h3 style=\"color:#1C1C75;font-size:1rem;font-weight:700;margin:0 0 10px;\">Aseptic Control at Scale<\/h3>\n        <p style=\"color:#5a5a7a;font-size:0.87rem;line-height:1.7;margin:0;\">Aseptic manufacturing requires consistent quality governance, controlled environments, RABS technology, audit readiness and compliant fill-finish execution.<\/p>\n      <\/div>\n      <div style=\"flex:1;min-width:280px;background-color:#ffffff;border:1px solid #e2e4f0;border-top:3px solid #0EC9BB;border-radius:12px;padding:24px;box-shadow:0 2px 10px rgba(28,28,117,0.06);\">\n        <div style=\"font-size:1.4rem;margin-bottom:12px;\">\ud83d\udce6<\/div>\n        <h3 style=\"color:#1C1C75;font-size:1rem;font-weight:700;margin:0 0 10px;\">Supply Continuity<\/h3>\n        <p style=\"color:#5a5a7a;font-size:0.87rem;line-height:1.7;margin:0;\">Manufacturing partners must support the full journey \u2014 from clinical development to commercial supply \u2014 with flexibility and long-term operational commitment.<\/p>\n      <\/div>\n      <div style=\"flex:1;min-width:280px;background-color:#ffffff;border:1px solid #e2e4f0;border-top:3px solid #0EC9BB;border-radius:12px;padding:24px;box-shadow:0 2px 10px rgba(28,28,117,0.06);\">\n        <div style=\"font-size:1.4rem;margin-bottom:12px;\">\ud83d\udccb<\/div>\n        <h3 style=\"color:#1C1C75;font-size:1rem;font-weight:700;margin:0 0 10px;\">Regulatory CMC Readiness<\/h3>\n        <p style=\"color:#5a5a7a;font-size:0.87rem;line-height:1.7;margin:0;\">CMC submissions, stability studies, analytical validation and multi-authority compliance add significant complexity across every product stage.<\/p>\n      <\/div>\n      <div style=\"flex:1;min-width:280px;background-color:#ffffff;border:1px solid #e2e4f0;border-top:3px solid #0EC9BB;border-radius:12px;padding:24px;box-shadow:0 2px 10px rgba(28,28,117,0.06);\">\n        <div style=\"font-size:1.4rem;margin-bottom:12px;\">\ud83c\udf10<\/div>\n        <h3 style=\"color:#1C1C75;font-size:1rem;font-weight:700;margin:0 0 10px;\">Clinical-to-Commercial Continuity<\/h3>\n        <p style=\"color:#5a5a7a;font-size:0.87rem;line-height:1.7;margin:0;\">Bridging clinical batches to commercial supply requires an integrated CDMO partner with depth across dosage forms \u2014 not disconnected service modules.<\/p>\n      <\/div>\n    <\/div>\n    <div style=\"background-color:#ffffff;border:1px solid #d0f0ee;border-left:4px solid #0EC9BB;border-radius:12px;padding:20px 28px;\">\n      <p style=\"color:#3a3a5a;font-size:0.95rem;line-height:1.75;margin:0;\"><strong style=\"color:#0EC9BB;\">The right CDMO partner<\/strong> can help reduce these risks by combining technical depth, quality-driven execution and a network able to adapt as your product needs evolve \u2014 from first GMP batch to high-volume commercial supply.<\/p>\n    <\/div>\n  <\/div>\n<\/div>\n\n\n<p><!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 --><br \/><!-- 5. LEARNING OUTCOMES                                      --><br \/><!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 --><\/p>\n\n\n<p class=\"has-text-color wp-block-paragraph\" style=\"color:#0EC9BB;font-size:11px;font-weight:700;letter-spacing:3px;text-transform:uppercase\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left has-text-color\" style=\"color:#1C1C75\">Practical insights to help reduce programme risk<\/h2>\n\n\n\n<p class=\"has-text-align-left wp-block-paragraph\">During the webinar, Adragos Pharma experts will share how an integrated sterile CDMO model can support customers across key stages of the product lifecycle. <strong>You will learn how to:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Identify what to look for in a sterile fill-finish CDMO partner<\/li>\n\n\n\n<li>Reduce technical risk during lyophilisation qualification and scale-up<\/li>\n\n\n\n<li>Improve speed and consistency through structured technology transfer<\/li>\n\n\n\n<li>Integrate products into sterile manufacturing facilities with a clear execution model<\/li>\n\n\n\n<li>Use a flexible sterile network to support clinical-to-commercial supply<\/li>\n<\/ul>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-buttons has-custom-font-size has-medium-font-size is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-fe48e5de wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-secondary-background-color has-background wp-element-button\" href=\"https:\/\/share-eu1.hsforms.com\/1FVbF5kKkQ4ac7mORaiFYmwfxkpu\" target=\"_blank\" rel=\"noopener\"><strong>Watch the Webinar<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<p class=\"has-text-align-center has-text-color wp-block-paragraph\" style=\"color:#0EC9BB;font-size:11px;font-weight:700;letter-spacing:3px;text-transform:uppercase\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center has-text-color\" style=\"color:#1C1C75\">Two practical case studies<\/h2>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\">Real-world examples of how Adragos Pharma experts approach sterile programme challenges, from qualification through to commercial execution.<\/p>\n\n\n\n<div style=\"height:8px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column rounded-xl border border-primary has-light-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:var(--wp--preset--spacing--50);padding-right:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50);padding-left:var(--wp--preset--spacing--50)\">\n<p class=\"has-text-color wp-block-paragraph\" style=\"color:#0EC9BB;font-size:11px;font-weight:700;letter-spacing:2.5px;text-transform:uppercase\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading has-text-color\" style=\"color:#1C1C75\">Lyophilisation Qualification and Scale-Up<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Learn how lyophilisation performance, product temperature mapping, sublimation behaviour and process robustness can be assessed to support scale-up from clinical to commercial manufacturing.<\/p>\n\n\n\n<p class=\"has-text-color wp-block-paragraph\" style=\"color:#5a5a7a;font-size:0.82rem\"><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column rounded-xl border border-secondary has-light-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:var(--wp--preset--spacing--50);padding-right:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50);padding-left:var(--wp--preset--spacing--50)\">\n<p class=\"has-text-color wp-block-paragraph\" style=\"color:#0EC9BB;font-size:11px;font-weight:700;letter-spacing:2.5px;text-transform:uppercase\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading has-text-color\" style=\"color:#1C1C75\">Product Integration into a Sterile Manufacturing Facility<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Explore how a structured, site-independent approach to technology transfer can support faster, more consistent product integration across a CDMO network.<\/p>\n\n\n\n<p class=\"has-text-color wp-block-paragraph\" style=\"color:#5a5a7a;font-size:0.82rem\"><\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-buttons has-custom-font-size has-medium-font-size is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-fe48e5de wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-primary-background-color has-background has-text-align-center wp-element-button\" href=\"https:\/\/share-eu1.hsforms.com\/1FVbF5kKkQ4ac7mORaiFYmwfxkpu\" target=\"_blank\" rel=\"noopener\"><strong><strong>Watch the Webinar<\/strong><\/strong><\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left has-secondary-color has-text-color has-link-color wp-elements-1618d972d8d094d1ee93fd0c6823956d\">A growing sterile network for clinical-to-commercial support<\/h2>\n\n\n\n<p class=\"has-text-align-left wp-block-paragraph\">Adragos Pharma\u2019s sterile manufacturing network combines aseptic fill-finish, lyophilisation, inspection, packaging and quality-driven execution across multiple sites.<\/p>\n\n\n\n<p class=\"has-text-align-left wp-block-paragraph\">Our sterile capabilities include prefilled syringes, liquid and lyophilised vials, ampoules, inspection, packaging and commercial manufacturing support. The Sterile Cluster brochure positions Adragos as a global integrated partner from clinical manufacturing to high-volume global supply.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With Maisons-Alfort and Jura as key sterile sites, Adragos Pharma is strengthening its ability to support customers with both commercial-scale execution and clinical-to-commercial flexibility.<\/p>\n\n\n\n<section class=\"wp-block-adragos-blocks-advanced-boxes max-w-screen-xl mx-auto px-8 py-16 md:py-20\">\n  <div class=\"grid grid-cols-1 md:grid-cols-3 gap-8\">\n    <div class=\"relative box bg-light rounded-xl p-8\">\n      <div class=\"flex gap-5 items-center box-title\">\n        <img decoding=\"async\" class=\"box-image\" src=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2024\/03\/France.svg\" alt=\"\"\/>\n        <a href=\"https:\/\/adragos-pharma.com\/livron-france\/\" class=\"box-link text-secondary font-medium\"><h3>Livron, France<\/h3><\/a>\n      <\/div>\n      <p class=\"my-6 box-subtitle\">Batch sizes from 30 to 1,500 L <br>Aseptic filling or terminal sterilisation process by heat<\/p>\n      <a href=\"https:\/\/adragos-pharma.com\/livron-france\/\" class=\"box-link text-secondary font-medium text-4xl\">\u27f6<\/a>\n    <\/div>\n    <div class=\"relative box bg-light rounded-xl p-8\">\n      <div class=\"flex gap-5 items-center box-title\">\n        <img decoding=\"async\" class=\"box-image\" src=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2024\/11\/istockphoto-691333880-612x612-1.jpg\" alt=\"\"\/>\n        <a href=\"https:\/\/adragos-pharma.com\/jura-switzerland\/\" class=\"box-link text-secondary font-medium\"><h3>Jura, Switzerland<\/h3><\/a>\n      <\/div>\n      <p class=\"my-6 box-subtitle\">Clinical and small-scale commercial manufacturing<br>Sterile liquids, suspension, emulsion, viscous liquids and lyophilised<br>Glass vials size: 2R, 6R, 10R, 20R, 30R\u200b<\/p>\n      <a href=\"https:\/\/adragos-pharma.com\/jura-switzerland\/\" class=\"box-link text-secondary font-medium text-4xl\">\u27f6<\/a>\n    <\/div>\n    <div class=\"relative box bg-light rounded-xl p-8\">\n      <div class=\"flex gap-5 items-center box-title\">\n        <img decoding=\"async\" class=\"box-image\" src=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2024\/03\/France.svg\" alt=\"\"\/>\n        <a href=\"https:\/\/adragos-pharma.com\/maisons-alfort-france\/\" class=\"box-link text-secondary font-medium\"><h3>Maisons-Alfort, France<\/h3><\/a>\n      <\/div>\n      <p class=\"my-6 box-subtitle\">Manufacturing of PFS and vials supported by CIP\/SIP and active RABS technologies.<br><br>PFS: 0,5 mL and 1 mL <br>Vials: 6R, 10R, 7 mL, 10 mL, 15 mL, 22 mL<\/p>\n      <a href=\"https:\/\/adragos-pharma.com\/maisons-alfort-france\/\" class=\"box-link text-secondary font-medium text-4xl\">\u27f6<\/a>\n    <\/div>\n  <\/div>\n<\/section>\n\n\n<h2 style=\"text-align: left;\">Meet Our Speakers<\/h2>\n<section class=\"speakers-section\">\n<div class=\"speakers-heading\" style=\"text-align: left;\">\n<h3>Highly skilled and well-trained scientists focused on development.<\/h3>\n<\/div>\n<p style=\"text-align: left;\"><!-- Speaker 1 \u2014 Bio LEFT, Photo RIGHT --><\/p>\n<div class=\"speaker-row\" style=\"text-align: left;\">\n<div class=\"speaker-bio\">\n<h3 class=\"speaker-name\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-25403\" src=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/05\/Paul-Marant-300x300.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/05\/Paul-Marant-300x300.png 300w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/05\/Paul-Marant-1024x1024.png 1024w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/05\/Paul-Marant-150x150.png 150w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/05\/Paul-Marant-768x768.png 768w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/05\/Paul-Marant-760x760.png 760w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/05\/Paul-Marant.png 1254w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>Paul Marnat<\/h3>\n<p><span class=\"speaker-title\">Head of Tech Transfer, Maisons-Alfort<\/span><\/p>\n<p class=\"speaker-text\">Paul Marnat is a pharmacist with more than 12 years of leadership experience in sterile pharmaceutical manufacturing, specialising in aseptic operations, GMP compliance, and technology transfer.<br \/>Over the course of his career, he has held key manufacturing leadership roles across several Sanofi injectable manufacturing sites, overseeing operations and delivering complex industrial projects, including aseptic process transfers and product launches.<br \/>Following the 2026 acquisition of Sanofi&#8217;s Maisons-Alfort injectable manufacturing site by Adragos Pharma, Paul has served as Head of Customer Service &amp; Tech Transfer at Adragos Pharma.<br \/>He now leads customer-facing activities and technology transfer programmes, partnering closely with internal teams to deliver efficient product transfers and dependable fill-finish operations.<\/p>\n<\/div>\n<\/div>\n<p style=\"text-align: left;\"><!-- Speaker 2 \u2014 Photo LEFT, Bio RIGHT --><\/p>\n<div class=\"speaker-row reverse\" style=\"text-align: left;\">\n<div class=\"speaker-bio\">\n<h3 class=\"speaker-name\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-18614\" src=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2025\/06\/Posts-for-LI-38-300x300.jpg\" alt=\"\" width=\"300\" height=\"300\" srcset=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2025\/06\/Posts-for-LI-38-300x300.jpg 300w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2025\/06\/Posts-for-LI-38-1024x1024.jpg 1024w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2025\/06\/Posts-for-LI-38-150x150.jpg 150w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2025\/06\/Posts-for-LI-38-768x768.jpg 768w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2025\/06\/Posts-for-LI-38-760x760.jpg 760w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2025\/06\/Posts-for-LI-38.jpg 1200w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>Guillaume Mollandin<\/h3>\n<p><span class=\"speaker-title\">Head of Engineering and PMO, Jura<\/span><\/p>\n<p class=\"speaker-text\">Guillaume Mollandin is a microbiology engineer with more than 14 years of progressive leadership in pharmaceutical manufacturing and project management. He began his career advancing from Manufacturing Manager in aseptic filling and visual inspection to Head of Packaging Operations. In 2020 he joined another company as Head of Fill-Finish Operations. From 2021 to 2023 he led aseptic fill-finish process development and served as MSAT Head for a DPS growth project. Since November 2024, Guillaume has been Head of Engineering &amp; Project Management (PMO) at Adragos Pharma&#8217;s Jura site, spearheading flexible, customer-focused fill-finish solutions.<\/p>\n<\/div>\n<\/div>\n<p style=\"text-align: left;\"><!-- Speaker 3 \u2014 Bio LEFT, Photo RIGHT --><\/p>\n<div class=\"speaker-row\">\n<div class=\"speaker-bio\" style=\"text-align: left;\">\n<h3 class=\"speaker-name\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-23930\" src=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/03\/tobias-schlogl-300x300.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/03\/tobias-schlogl-300x300.png 300w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/03\/tobias-schlogl-1024x1024.png 1024w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/03\/tobias-schlogl-150x150.png 150w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/03\/tobias-schlogl-768x768.png 768w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/03\/tobias-schlogl-760x760.png 760w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/03\/tobias-schlogl.png 1080w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>Tobias Schl\u00f6gl<\/h3>\n<p><span class=\"speaker-title\">Business Development Director<\/span><\/p>\n<p class=\"speaker-text\">Tobias joined Adragos Pharma in February 2026 as Business Development Director and brings 20 years of experience in the pharmaceutical industry with profound know-how in sterile drug product manufacturing and pharmaceutical services. Working several years for Vetter Pharma, he held various positions including Quality Assurance, Project Management and, most recently, as a Business Development Manager. In addition, he was several years Head of Drug Product Manufacturing aseptic production at Boehringer Ingelheim.<br \/>At Adragos Pharma, Tobias is focusing on fill &amp; finish services. In his role he also supports the sales and marketing team and helps broaden the expertise and network for small molecules and biologic products. He contributes with his understanding of production and quality, combined with the ability to translate complex technical topics into value-added solutions for partners and stakeholders.<\/p>\n<\/div>\n<div class=\"speaker-image\">\u00a0<\/div>\n<\/div>\n<\/section>\n\n\n<div style=\"height:47px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<section class=\"wp-block-adragos-blocks-footer-cta max-w-screen-lg bg-light mx-8 md:mx-auto px-8 py-12 text-center mt-3 mb-12 md:mb-16 rounded-xl\"><h2 class=\"\">Contact us<\/h2><p class=\"subtitle font-light m-auto max-w-screen-sm py-6\">For more information about our company and services, please feel free to reach out to our team.<\/p><div class=\"flex flex-col md:flex-row justify-center gap-4\"><a href=\"https:\/\/adragos-pharma.com\/contact-us\/?utm_campaign=MK_website_contactUs&amp;utm_source=website_homepage\" class=\"cta-link inline-block adragos-button text-white has-primary-background-color text-center\">Send a message<\/a><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"<p>De-Risking Sterile Fill-Finish from Clinical to Commercial How expanded CDMO capabilities, lyophilisation expertise and a flexible facility network help accelerate sterile product success. Sterile product development and manufacturing can be complex. Scale-up, lyophilisation, technology transfer, quality expectations and supply continuity [&hellip;]<\/p>\n","protected":false},"author":17,"featured_media":26269,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[17],"tags":[],"topics":[],"locations":[],"experts":[],"class_list":["post-26202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events"],"_links":{"self":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/26202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/comments?post=26202"}],"version-history":[{"count":39,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/26202\/revisions"}],"predecessor-version":[{"id":26267,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/26202\/revisions\/26267"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media\/26269"}],"wp:attachment":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media?parent=26202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/categories?post=26202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/tags?post=26202"},{"taxonomy":"topics","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/topics?post=26202"},{"taxonomy":"locations","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/locations?post=26202"},{"taxonomy":"experts","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/experts?post=26202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}